scholarly journals Effect of Ruboxistaurin on Blood–Retinal Barrier Permeability in Relation to Severity of Leakage in Diabetic Macular Edema

2005 ◽  
Vol 46 (10) ◽  
pp. 3855 ◽  
Author(s):  
Charlotte Strøm ◽  
Birgit Sander ◽  
Kristian Klemp ◽  
Lloyd Paul Aiello ◽  
Henrik Lund-Andersen ◽  
...  
1998 ◽  
Vol 8 (3) ◽  
pp. 127-130 ◽  
Author(s):  
J. Cunha-Vaz

Retinal edema is defined as any increase of water in retinal tissue resulting in an increase in its volume. This increase may be initially intracellular or extracellular. In the first case, there is cytotoxic edema. In the second, vasogenic edema, directly associated with an alteration of the blood-retinal barrier (BRB). Retinal thickness can now be measured, using the retinal thickness analyser (RTA). Similarly, local breakdown of the BRB can now be mapped using the retinal leakage analyser (RLA). The application of these methods to diabetic macular edema has shown that both types of retinal retinopathy edema occur in the initial stages of diabetic retinal disease. These observations suggest a role for neuroprotective and vasoprotective agents in the management of diabetic retinal disease.


2017 ◽  
Vol 44 ◽  
pp. 182-189 ◽  
Author(s):  
Grazia Maugeri ◽  
Agata Grazia D'Amico ◽  
Daniela Maria Rasà ◽  
Valentina La Cognata ◽  
Salvatore Saccone ◽  
...  

2016 ◽  
Vol 23 (04) ◽  
pp. 478-483
Author(s):  
Muhmmad Jameel Shahid ◽  
Faheem Ahmad ◽  
Muhammad Asif ◽  
Muhmmad Nabeel Sultan

Regarding the causes of blindness, Diabetic retinopathy is a one the majorcause of blindness in all types persons from both industrialized and developing countries.Due to inadequate eating habits, prevalence of diabetic retinopathy is increasing. Both focaland diffuse leakage from retinal capillaries can cause Diabetic macular edema. Varioustreatment modalities for macular photocoagulation are focal laser, Grid laser and modified gridused in patients having diabetic macular edema Study Design: Prospective, interventional,noncompetitive case series. Setting: Department of Ophthalmology, Allied Hospital andDepartment of Ophthalmology, Divisional Headquarter Hospital Faisalabad. Period: One yearfrom April 2012 to April 2013. Materials and Methods: A total of 200 eyes of 200 patientswith clinical significant macular edema that met the inclusion criteria were enrolled. Results: Inthis study, 200 patients with diabetic macular edema were studied. Of these 121 (60.5%) weremales and 79 (39.5%) females with mean age of 38.52 years (SD 7.512, Range 25-50 years).All patients had diffuse, clinically significant macular edema at baseline for which they hadreceived grid laser photocoagulation. Discussion: In recent past number of diabetic patientsall over the world has increased that has caused increase incident of diabetic retinopathy .Soin patients having diabetic retinopathy, macular edema can cause deterioration in visual acuityduring any stage of diabetic retinopathy. The pathogenesis of Diabetic macular edema (DME)is the disruption of inner blood – retinal barrier that is known to be associated with metabolicalteration affecting the retinal pigment epithelium or retinal vascular endothelium. Focal and/orgrid laser photocoagulation is being considered as the treatment of DME. Conclusion: Macularphotocoagulation was found to be an effective method of treatment for CSME among diabeticpatients, which has resulted in a positive visual outcome in 87% of the patients (stable andimproved vision).


2017 ◽  
Vol 118 (8) ◽  
pp. 2371-2379 ◽  
Author(s):  
Grazia Maugeri ◽  
Agata Grazia D'Amico ◽  
Daniela Maria Rasà ◽  
Valentina La Cognata ◽  
Salvatore Saccone ◽  
...  

2021 ◽  
Vol 22 (7) ◽  
pp. 3427
Author(s):  
Hidetaka Noma ◽  
Kanako Yasuda ◽  
Masahiko Shimura

Diabetic macular edema (DME) is a critical complication of diabetic retinopathy, a condition that arises from the breakdown of the blood–retinal barrier and the consequent increase in vascular permeability. Over the years, attempts have been made to treat DME by various approaches, including laser photocoagulation, steroid triamcinolone acetonide, and vitrectomy. However, treatment was unsatisfactory until research identified vascular endothelial growth factor (VEGF) as a factor in the pathogenesis of DME. Intraocular anti-VEGF agents show good efficacy in DME. Nevertheless, in some patients the condition recurs or becomes resistant to treatment, suggesting that other factors may be involved. Because inflammation and retinal hypoxia are seen in DME, research has examined the potential role of cytokines and other inflammatory mediators. In this review, we provide an overview of this research and describe feedback mechanisms that may represent a target for novel treatments.


2016 ◽  
Vol 232 (5) ◽  
pp. 1079-1085 ◽  
Author(s):  
Grazia Maugeri ◽  
Agata Grazia D'Amico ◽  
Caterina Gagliano ◽  
Salvatore Saccone ◽  
Concetta Federico ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document